Human papillomavirus-related penile squamous cell carcinoma
MONDO:0020656A squamous cell carcinoma that arises from the penis and is caused by human papillomavirus infection. Morphologic variants include basaloid carcinoma and warty carcinoma.
Also known as: HPV-related penile squamous cell carcinoma, human papilloma virus related penile squamous cell carcinoma, human papilloma virus-related penile squamous cell carcinoma, human papillomavirus-related penile squamous cell carcinoma
2764 clinical trials for this condition and its sub-types, 8 tagged with Human papillomavirus-related penile squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Human papillomavirus-related penile squamous cell carcinoma
-
Basaloid carcinoma of the penis 0 trials
-
Warty carcinoma of the penis 0 trials
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HPV cancers
Disease control OngoingThis study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to se…
Phase 1/2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingThis early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…
Phase 1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC